IP Library Granted Patent US 8,962,818
Granted Patent B2
US 8,962,818 · App. 12/920,545 · Granted Feb 24, 2015

Compositions comprising GHRH and GnRH and methods of using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,962,818
App. No.
12/920,545
Granted
Feb 24, 2015
Kind
B2
Abstract

Compositions and kits comprising a nucleotide sequence that encodes GHRH and a nucleotide sequence that encodes GnRH and compositions and kits comprising a GHRH protein and GnRH protein are disclosed. Use of such compositions and kits in methods of enhancing fertility in mammals comprising the step of administering said compositions to the mammal are disclosed.

Claims (9)

1. A pharmaceutical composition formulated for administration to a mammal in order to introduce to a cell of the mammal a GHRH product and a GnRH product, wherein the GHRH product comprises a nucleotide sequence that encodes GHRH and the GnRH product comprises a nucleotide sequence that encodes GnRH, and

wherein the nucleotide sequence that encodes GHRH is a plasmid having a nucleotide sequence as set forth in SEQ ID NO: 4 and the nucleotide sequence that encodes GnRH is a plasmid having a nucleotide sequence as set forth in SEQ ID NO: 1.

2. A kit comprising a first container comprising a nucleotide sequence that encodes GHRH and a second container comprising a nucleotide sequence that encodes GnRH, wherein the nucleotide sequence that encodes GHRH has a nucleotide sequence as set forth in SEQ ID NO: 4 and the nucleotide sequence that encodes GnRH has a nucleotide sequence as that set forth in SEQ ID NO: 1.

3. A method of enhancing fertility in a mammal in need thereof, the method comprising the step of administering to said mammal the pharmaceutical composition of claim 1 .

4. The method according to claim 3 , wherein the step of administering the pharmaceutical composition comprises injecting intramuscular, injecting intradermally, injecting intravenously, or delivering transdermally.

5. The method according to claim 3 , further comprising the step of electroporating tissue of the mammal after the step of administering the pharmaceutical composition.

6. The method according to claim 5 , comprising electroporating the tissue of the mammal using constant current.

7. The method according to claim 3 , wherein the mammal is selected from the group consisting of: horses, dogs, cats, pigs, cows, sheep, goats, and primates.

8. The method according to claim 3 , wherein the mammal exhibits enhanced fertility over an untreated mammal.

Assignments (3)
MERGER Recorded Feb 2, 2021
From: VGX PHARMACEUTICALS, LLC
To: INOVIO PHARMACEUTICALS, INC.
Reel/Frame 055114/0843 →
MERGER AND CHANGE OF NAME Recorded Dec 21, 2020
From: VGX PHARMACEUTICALS, INC.; INOVIO ACQUISITION, LLC
To: VGX PHARMACEUTICALS, LLC
Reel/Frame 054704/0830 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2015
From: DRAGHIA-AKLI, RUXANDRA; BROWN, PATRICIA; KHAN, AMIR
To: VGX PHARMACEUTICALS, INC
Reel/Frame 034670/0220 →